Bart O. Williams

Keywords proteogenomics lung adenocarcinoma genomics mass spectrometry PTMs biomarkers smokers never-smokers CPTAC ICPC Introduction Lung adenocarcinomas (LUAD), the most prevalent subtype of non-small cell lung cancers (NSCLC), represent a significant global health challenge with marked geographical and epidemiological diversity in incidence and disease progression.1 Despite advances in targeted therapies and improved diagnostic techniques, LUAD continue to exhibit high mortality rates,2...

The allegation sounded serious: defendant Gilead Sciences was accused of having struck an anticompetitive pay-for-delay patent deal with a generic manu­facturer that harmed people with HIV. The plaintiffs sought $3.6 billion. But lawyers from Proskauer Rose LLP, Kirkland & Ellis LLP and Goodwin Procter LLP — making up a trial team led by Proskauer's Bart H.

1. Introduction The Beginning of “Transgenic” Mice Mouse models of human disease have played critical roles in biomedical research. Forward genetics screens, where phenotypic screening of organisms with spontaneous or randomly induced mutations (for example, following ENU treatment) followed by subsequent identification of the underlying genetic alteration, have contributed to understanding skeletal development and disease [1,2,3,4].